1,448
Views
0
CrossRef citations to date
0
Altmetric
Author’s Views

Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Article: 1994328 | Received 04 Oct 2021, Accepted 12 Oct 2021, Published online: 14 Jan 2022

References

  • Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841–3.
  • Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495–509.
  • Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, et al. Genetic determinants of EGFR-driven lung cancer growth and therapeutic response In vivo. Cancer Discov. 2021;11(7):1736–1753. doi:10.1158/2159-8290.CD-20-1385.
  • Rogers ZN, McFarland CD, Winters IP, Naranjo S, Chuang CH, Petrov D, Winslow MM . A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods. 2017;14:737–742 doi:10.1038/nmeth.4297.
  • Rogers ZN, McFarland CD, Winters IP, Seoane JA, Brady JJ, Yoon S, et al. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet. 2018;50:483–486 doi:10.1038/s41588-018-0083-2.
  • Winters IP, Murray CW, Winslow MM. Towards quantitative and multiplexed in vivo functional cancer genomics. Nat Rev Genet. 2018;19(12):741–755. doi:10.1038/s41576-018-0053-7.
  • van de Haar J, Canisius S, Yu MK, Voest EE, Wessels LFA, Ideker T. Identifying epistasis in cancer genomes: a delicate affair. Cell. 2019;177:1375–1383.
  • Cai H, Chew SK, Li C, Tsai MK, Andrejka L, Murray CW, et al. A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. Cancer Discov. 2021;11(7):1754–1773.
  • Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
  • Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-Mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–1723.
  • Li C, Lin WY, Rizvi H, Cai H, McFarland CD, Rogers ZN, et al. Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma. Cancer Res. 2021;81(17):4570–4580.